The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome.
Jiameng RenYanmin YangJun ZhuShuang WuJuan WangHan ZhangXinghui ShaoPublished in: Pacing and clinical electrophysiology : PACE (2020)
Intravenous amiodarone might be an alternative for acute treatment of AF and WPW syndrome in patients characterized by stable hemodynamics, relatively low admission heart rate, few comorbidities, elder age, and no prior syncope. The loading dosage of 150 mg appeared to be preferred, and the maintenance period was better to less than 12 hours. Monitoring and electrolyte correction were also necessary. It is essential to keep a defibrillator nearby during pharmacologic cardioversion.
Keyphrases
- heart rate
- end stage renal disease
- heart rate variability
- atrial fibrillation
- blood pressure
- ejection fraction
- newly diagnosed
- emergency department
- chronic kidney disease
- liver failure
- peritoneal dialysis
- case report
- prognostic factors
- pulmonary embolism
- ionic liquid
- aortic dissection
- low dose
- acute respiratory distress syndrome
- replacement therapy
- mechanical ventilation